Work

Omaveloxolone for the Treatment of Friedreich Ataxia: Efficacy, Safety, and Future Perspectives

Year: 2024

Type: article

Abstract: Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Source: Movement Disorders

DOI: 10.1002/mds.30070

Authors: Saba Naghipour, Louise A. Corben, Amy J. Hulme, Mirella Dottori, Martin B. Delatycki, Jarmon G. Lees, Shiang Y. Lim

Institutions: O'Brien Institute, St Vincents Institute of Medical Research, The University of Melbourne, Murdoch Children's Research Institute, University of Wollongong, Victorian Clinical Genetics Services, Monash University, National Heart Centre Singapore

Language: English

Topic: Genetic Neurodegenerative Diseases

Subfield: Cellular and Molecular Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Friedreich's Ataxia Research Alliance, National Ataxia Foundation, National Health and Medical Research Council

Awards: G4029735265, G4505351877, G5762936922, G7017194298, Advancing new therapies for Friedreich ataxia heart disease

OpenAlex ID: W4404504450

FWCI: 1.88

Cites: 38

Cited by: 12

Related to: 10